The default is to continue therapy
For most of the twentieth century, the reflex before a tooth extraction or an implant placement in an anticoagulated patient was to stop the drug. That reflex was wrong, and the modern evidence has overturned it decisively. The thrombotic harm of interrupting therapy — stroke, systemic embolism, stent thrombosis, myocardial infarction — is real, sometimes catastrophic, and accumulates over the very days the clinician imagines they are buying safety. The bleeding harm of continuing therapy through routine oral surgery, by contrast, is almost always manageable at the chairside with local measures. The contemporary default, endorsed across national guidance, is therefore unambiguous: do not interrupt anticoagulant or antiplatelet therapy for routine dental surgery; continue the drug and control bleeding locally.12
This chapter translates that principle into a class-by-class management algorithm. The agents divide into three families that behave differently at the chairside: the vitamin K antagonist warfarin, which is monitored by the international normalized ratio (INR) and is continued when the INR is below 4.0; the direct oral anticoagulants (DOACs) — apixaban, rivaroxaban, dabigatran, edoxaban — which are given at fixed dose, require no routine monitoring, are usually continued, and must never be bridged with heparin; and the antiplatelets — aspirin, clopidogrel, and dual antiplatelet therapy (DAPT) — which are not interrupted for routine dental surgery and, after recent coronary stenting, are never stopped without cardiology agreement. The common thread is that none of these decisions is made unilaterally by the dentist. The principle that runs through every cell of the algorithm is the same one that protects the patient: never stop or bridge an anticoagulant unilaterally — any interruption is a physician-led decision based on thrombotic risk.23
The decision is not "is there a bleeding risk?" — there always is — but "does the bleeding risk of this procedure, with full local hemostasis in place, exceed the thrombotic risk of interruption?" For routine implant placement and simple extractions, the answer is almost always no. Continuation is safe because robust local hemostasis is planned and available; the two are inseparable. Escalation to deferral or referral is reserved for the narrow intersection of high thrombotic risk plus extensive surgery, and is always taken with the prescriber.
Identify the agent first
Because management diverges by drug class, the first chairside step is always to identify precisely which agent — or combination of agents — the patient is taking, and to confirm the indication (atrial fibrillation, mechanical valve, recent stent, prior venous thromboembolism) that sets the thrombotic stakes. The table below summarizes the management posture for each class; the sections that follow develop each in turn.
| Agent class | Representative drugs | Monitoring | Routine-surgery management | Evidence |
|---|---|---|---|---|
| Vitamin K antagonist | Warfarin | INR within 24–72 h | Continue if INR < 4.0; full local hemostasis; do not bridge | Guidance |
| DOAC | Apixaban, rivaroxaban, dabigatran, edoxaban | None routine | Usually continue; consider dose timing per prescriber; never bridge | Syst. review |
| Antiplatelet (single) | Aspirin, clopidogrel | None | Do not interrupt; local hemostasis suffices | Syst. review |
| Dual antiplatelet (DAPT) | Aspirin + P2Y₁₂ inhibitor | None | Do not interrupt; never stop post-stent without cardiology | Guidance |
| Combined / extensive | Multiple agents; major augmentation | Per agent | Coordinate / refer; physician-led shared decision | Guidance |
Warfarin, DOACs, and antiplatelets in turn
Warfarin — continue if INR is below 4.0
Therapeutic warfarin can usually be continued for routine implant surgery. The single decisive datum is a recent INR, obtained within 24–72 hours of the procedure — closer if the patient's control is known to be unstable. If the INR is below 4.0, proceed with the full local hemostasis toolkit in place.2 If the INR is 4.0 or above, or if a recent value is unavailable, defer and liaise with the prescriber rather than guessing. Extensive surgery in a warfarinized patient can be staged into smaller visits to keep each bleeding burden small. Crucially, warfarin is not bridged with low-molecular-weight heparin for routine dental work; bridging adds bleeding risk without a corresponding reduction in thrombosis and is reserved for specific high-thrombotic-risk situations decided by the physician.1
DOACs — usually continue, never bridge
The direct oral anticoagulants are given at fixed dose and need no INR or routine coagulation monitoring, which removes the temptation to "check and adjust." For routine procedures, the DOAC is continued with local measures.1 For higher-bleed-risk cases, the prescriber may advise timing the surgery at the drug's trough or omitting or delaying the morning dose — but this is a dose-timing nuance, not an interruption, and is decided with the physician. There is no bridging of DOACs: their short half-lives make heparin bridging both unnecessary and harmful. Renal function deserves a glance in higher-risk patients because impaired clearance prolongs DOAC effect, and normal dosing is resumed once hemostasis is secure, typically the same or next day.3
Antiplatelets and DAPT — do not interrupt
Stopping antiplatelet therapy for dental surgery exposes the patient to thrombotic risk while conferring little bleeding benefit, and is not indicated. Aspirin, clopidogrel, and dual antiplatelet therapy are all continued for routine implant placement and extraction; the resulting bleeding is reliably managed with local hemostasis.2 The most dangerous error in this group is interrupting DAPT after recent coronary stenting: premature cessation in the months following stent placement is a recognized precipitant of stent thrombosis, which carries a high mortality. DAPT is never stopped on the dentist's initiative; any change is agreed with cardiology.3
When to coordinate or refer
Escalation is appropriate at the intersection of high thrombotic risk and extensive surgery — for example a patient on combined antithrombotic agents, or one requiring major bone augmentation with a large flap, particularly against a background of significant comorbidity. Here the path is shared decision-making: consult the prescribing physician on the thrombotic-versus-bleeding balance, consider staging the surgery, a hospital setting, or referral to oral and maxillofacial surgery, and remember that any interruption remains a physician-led decision rather than a unilateral one.
| Agent / scenario | Decision | Key safeguards |
|---|---|---|
| Warfarin (VKA) | Continue if INR < 4.0 | INR within 24–72 h; defer if ≥ 4.0; no bridging; stage if extensive |
| DOAC | Usually continue | No bridging; per-prescriber dose timing for high-bleed cases; check renal function; resume when hemostasis secure |
| Single antiplatelet | Do not interrupt | Local hemostasis suffices; stage if extensive |
| DAPT (post-stent) | Do not interrupt | Never stop without cardiology; highest thrombotic stakes |
| High bleed + extensive | Coordinate / refer | Physician-led shared decision; consider staging, hospital, or OMFS referral |
The toolkit that makes "continue" safe
Continuation is defensible only when robust local hemostasis is planned and immediately available. The measures below are not a menu of optional extras; together they constitute the standard of care that licenses the decision to continue therapy. Most are inexpensive, and their combined effect is what reduces the postoperative bleeding of an anticoagulated patient to a routinely controllable event.1 Topical tranexamic acid deserves particular emphasis: as a mouthrinse or gauze-soaked compress it produces a substantial reduction in postoperative bleeding in antithrombotic patients and is a mainstay of the modern toolkit.3
| Measure | How it works / how it is used | Evidence |
|---|---|---|
| Atraumatic technique | Minimize flap and tissue trauma; achieve primary closure where possible to reduce the raw bleeding surface | Guidance |
| Sutures | Stabilize the clot and approximate tissue margins over the socket or osteotomy | Guidance |
| Oxidized cellulose / collagen / gelatin sponge | Resorbable packing placed in the socket or osteotomy to scaffold clot formation | Syst. review |
| Tranexamic acid (topical) | Antifibrinolytic mouthrinse or gauze soak per local policy; meta-analytic reduction in postoperative bleeding | Syst. review |
| Pressure pack | Firm sustained bite on damp gauze; reinforced by clear written post-operative instructions | Guidance |
| Appointment timing | Schedule morning, early-week visits so any rebleed presents while care is readily available | Guidance |
Decide on your hemostatic stack — packing material, suture, tranexamic acid rinse, written instructions — before you raise a flap, not after the socket starts to ooze. The decision to continue anticoagulation and the decision to deploy full local hemostasis are a single decision. An early-week morning appointment also means that, in the rare event of a delayed rebleed, the patient reaches you during working hours rather than at midnight on a Friday.
- Telling a patient to stop warfarin, a DOAC, or DAPT on your own initiative — the single most dangerous error in this chapter, and never the dentist's call to make alone.
- Bridging a DOAC with heparin: it is unnecessary given short DOAC half-lives and adds bleeding risk without thrombotic benefit.
- Proceeding on warfarin without a recent INR, or proceeding when the INR is 4.0 or above.
- Interrupting DAPT in the months after coronary stenting — a recognized precipitant of stent thrombosis.
Interactive management selector
Match the agent and the bleeding complexity of the planned procedure. For routine implant placement and simple extractions, every anticoagulant and antiplatelet pathway resolves to continue plus local hemostasis. Escalate to defer or refer only for the narrow intersection of high thrombotic risk and extensive surgery — and always in concert with the prescribing physician. Select the patient's medication group to review the recommended management.
Whatever the selector returns, one principle is invariant: never stop or bridge an anticoagulant unilaterally. Continuation is the default; any interruption is a physician-led decision based on the patient's thrombotic risk, agreed with the prescriber — never taken alone at the chairside.
Key terms
- Anticoagulant
- A drug that interferes with the coagulation cascade to reduce clot formation; in dentistry the relevant agents are warfarin and the direct oral anticoagulants.
- Antiplatelet
- A drug that inhibits platelet aggregation (e.g., aspirin, clopidogrel), reducing arterial thrombosis; distinct in mechanism from anticoagulants.
- Vitamin K antagonist (VKA)
- Warfarin; inhibits vitamin-K-dependent clotting factor synthesis, with effect monitored by the INR.
- INR (International Normalized Ratio)
- A standardized measure of warfarin anticoagulation; routine dental surgery proceeds when the INR is below 4.0.
- DOAC (Direct Oral Anticoagulant)
- Fixed-dose oral anticoagulants — apixaban, rivaroxaban, dabigatran, edoxaban — that require no routine monitoring and are never bridged.
- DAPT (Dual Antiplatelet Therapy)
- Concurrent aspirin plus a P2Y₁₂ inhibitor (e.g., clopidogrel), commonly after coronary stenting; not interrupted without cardiology agreement.
- Bridging
- Substituting a short-acting anticoagulant (typically heparin) while a longer-acting one is held; not used for routine dental surgery and never for DOACs.
- Tranexamic acid
- An antifibrinolytic agent used topically (mouthrinse or gauze soak) to reduce postoperative oral bleeding.
- Stent thrombosis
- Acute clot formation within a coronary stent, a high-mortality event precipitated by premature interruption of antiplatelet therapy.
Board preparation
- What if the INR comes back at 4.3?
- When, if ever, would bridging be appropriate, and who decides?
- How does renal function alter your DOAC plan?
- When do you resume the DOAC after surgery?
- How would your answer change if the stent were five years old?
- Who do you contact, and what do you ask them?
- What evidence would you cite to a skeptical colleague?
- Name a scenario where the balance genuinely tips toward coordination.
- Which single measure has the strongest evidence, and why?
- What is your plan if the patient calls with a delayed bleed at home?
References
- American Dental Association. Oral anticoagulant and antiplatelet medications and dental procedures — Oral Health Topics. 2024. ada.org
- Scottish Dental Clinical Effectiveness Programme (SDCEP). Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs. 2nd ed. 2022. sdcep.org.uk
- Bajkin BV, Wahl MJ, Miller CS. Dental implant surgery and risk of bleeding in patients on antithrombotic medications: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;130(5):522–532. doi:10.1016/j.oooo.2020.07.012
Evidence grades: Systematic review National guidance / consensus Preclinical.